Sir, It is with great interest that we read the work of Pyle et al. (2014) on the utility of exome sequencing in achieving molecular diagnosis in ataxia. In particular, we take notice of the higher rate of 'confirmed pathogenic' and 'possible pathogenic' variants identified in this work as compared to others and question the stringency with which these classifications are applied. As stated by Pyle et al. (2014) , the 41% (9/22 families) confirmed pathogenic rate is more than 2-fold higher than the 18% (9/50 individuals) detection rate reported using large targeted gene panels (Németh et al., 2013) . This was explained by not using a limited gene panel in the Pyle et al. (2014) study, and possibly deeper coverage. However, Fogel et al. (2014) , applied whole-exome sequencing to ataxia and found a similarly low rate of pathogenic variants of 21% (16/76 individuals). In this letter we point out that while promising variants were presented by Pyle et al. (2014) , many molecular diagnoses that were claimed were based on data that were not entirely convincing, and are likely false-positive.
Claiming a variant as pathogenic has immediate implications for future clinical testing and counselling, as publications such as Pyle et al. (2014) are used as a peer-reviewed public record to evaluate if a clinical variant is disease-causing or not in future cases. Claiming a variant as confirmed pathogenic when the evidence is less than convincing may result in inaccurate diagnosis, inappropriate changes in medical treatment, inaccurate counselling in pre-natal and presymptomatic testing environments, or abortion of healthy foetuses.
A recent perspective in Nature provides recommendations as to what evidence would be needed to claim variant causality (MacArthur et al., 2014) . In agreement with these recommendations, we raise three types of concerns: (i) In all, we raise questions for three families with 'confirmed pathogenic' and four families with 'possibly pathogenic' classification. Due to the concerns presented in Table 1 , these variants warrant more cautious interpretation. (Porter et al., 2010) , hepatitis C infection (Arciello et al., 2012) and hyperlipidaemia (Arca et al., 2007) . These alternative explanations should be excluded before making a diagnosis.
Additional sequencing of unaffected siblings revealed that the siblings are not carriers of either variant and did not confirm whether these two mutations are compound heterozygous mutations (trans) or double mutants (cis).
Patient P20 with WFS1 variants Pyle et al. (2014) refers to the variants reported in WFS1 as known mutations that have been previously described in patients with Wolfram syndrome, citing Cryns et al. (2003) . However, these two mutations are not associated with Wolfram syndrome (Cryns et al., 2003) . Mutations in WFS1 can cause Wolfram syndrome, primarily characterized by juvenile diabetes and early onset optic atrophy, but neurodegenerative features such as ataxia can develop in many cases. Mutations in WFS1 are also associated with type 1 and type 2 diabetes and deafness. Cryns et al. (2003) , the Human Gene Mutation Database (Stenson et al., 2014) , along with other researchers, have noted an association between Arg456His and development of diabetes and between Lys193Gln and deafness. Neither of these variants has been previously associated with neurodegenerative symptoms or ataxia.
Patient P21 with FASTKD2 variants Pyle et al. (2014) used splicing prediction programs and found both a predicted gain and loss of an acceptor site. c.-66A4G sits in exon 1 in the 5'UTR of FASTKD2 near the splice donor site that does not appear to be impacted. The splice acceptor site at intron 1/exon 2 also does not appear to be impacted.
Patients P22, P23 and P24 with ZFYVE27 variants A heterozygous splice site variant in ZFYVE27 is reported in a dominant family (Pyle et al., 2014) . The Exome Aggregation Consortium (ExAC) reports 11 different splice, frameshift and stop gain variants in ZFYVE27, suggesting that haploinsufficiency alone isn't likely to cause disease (ExAC, 2015) . The reported splice site is not utilized in all transcripts for ZFYVE27, an additional splice site exists five amino acids further downstream, such that impact of possible differential splicing in the patients is unclear.
Summary
With these considerations the 'confirmed pathogenic' rate drops to 6/22 families (27.2%), similar to the 21% found by other exome data (Fogel et al., 2014) . These six families include the two childhood onset SACS variants families, the family with a previously reported KCNC3 variant, the family with previously reported SPG7 variants, and the two families with TUBB4A variants. We understand the importance of discovering a molecular diagnosis in currently undiagnosed cases of ataxia. It is incredibly frustrating for patients and physicians when there is no definitive explanation for a patient's symptoms. Reports of variants of interest are helpful to the scientific community to explore if other researchers have found the same damaging variant in similar phenotypes. However, when additional molecular evidence or other affected individuals do not exist, more caution should be exercised before claiming a particular variant as causative, as such claims may lead to false clinical tests in the future.
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